IBDEI057 ; ; 09-AUG-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,6426,1,4,0)
 ;;=4^I34.1
 ;;^UTILITY(U,$J,358.3,6426,2)
 ;;=^5007170
 ;;^UTILITY(U,$J,358.3,6427,0)
 ;;=D68.4^^26^402^1
 ;;^UTILITY(U,$J,358.3,6427,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6427,1,3,0)
 ;;=3^Acquired Coagulation Factor Deficiency
 ;;^UTILITY(U,$J,358.3,6427,1,4,0)
 ;;=4^D68.4
 ;;^UTILITY(U,$J,358.3,6427,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,6428,0)
 ;;=D59.9^^26^402^2
 ;;^UTILITY(U,$J,358.3,6428,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6428,1,3,0)
 ;;=3^Acquired Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,6428,1,4,0)
 ;;=4^D59.9
 ;;^UTILITY(U,$J,358.3,6428,2)
 ;;=^5002330
 ;;^UTILITY(U,$J,358.3,6429,0)
 ;;=C91.00^^26^402^5
 ;;^UTILITY(U,$J,358.3,6429,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6429,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,6429,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,6429,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,6430,0)
 ;;=C91.01^^26^402^4
 ;;^UTILITY(U,$J,358.3,6430,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6430,1,3,0)
 ;;=3^Acute Lymphoblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,6430,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,6430,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,6431,0)
 ;;=C92.01^^26^402^7
 ;;^UTILITY(U,$J,358.3,6431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6431,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,6431,1,4,0)
 ;;=4^C92.01
 ;;^UTILITY(U,$J,358.3,6431,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,6432,0)
 ;;=C92.00^^26^402^8
 ;;^UTILITY(U,$J,358.3,6432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6432,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,6432,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,6432,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,6433,0)
 ;;=C92.61^^26^402^9
 ;;^UTILITY(U,$J,358.3,6433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6433,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
 ;;^UTILITY(U,$J,358.3,6433,1,4,0)
 ;;=4^C92.61
 ;;^UTILITY(U,$J,358.3,6433,2)
 ;;=^5001808
 ;;^UTILITY(U,$J,358.3,6434,0)
 ;;=C92.60^^26^402^10
 ;;^UTILITY(U,$J,358.3,6434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6434,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
 ;;^UTILITY(U,$J,358.3,6434,1,4,0)
 ;;=4^C92.60
 ;;^UTILITY(U,$J,358.3,6434,2)
 ;;=^5001807
 ;;^UTILITY(U,$J,358.3,6435,0)
 ;;=C92.A1^^26^402^11
 ;;^UTILITY(U,$J,358.3,6435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6435,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
 ;;^UTILITY(U,$J,358.3,6435,1,4,0)
 ;;=4^C92.A1
 ;;^UTILITY(U,$J,358.3,6435,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,6436,0)
 ;;=C92.A0^^26^402^12
 ;;^UTILITY(U,$J,358.3,6436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6436,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,6436,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,6436,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,6437,0)
 ;;=C92.51^^26^402^13
 ;;^UTILITY(U,$J,358.3,6437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6437,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,6437,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,6437,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,6438,0)
 ;;=C92.50^^26^402^14
 ;;^UTILITY(U,$J,358.3,6438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6438,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,6438,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,6438,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,6439,0)
 ;;=C94.40^^26^402^17
 ;;^UTILITY(U,$J,358.3,6439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6439,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,6439,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,6439,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,6440,0)
 ;;=C94.42^^26^402^15
 ;;^UTILITY(U,$J,358.3,6440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6440,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,6440,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,6440,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,6441,0)
 ;;=C94.41^^26^402^16
 ;;^UTILITY(U,$J,358.3,6441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6441,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,6441,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,6441,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,6442,0)
 ;;=D62.^^26^402^18
 ;;^UTILITY(U,$J,358.3,6442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6442,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,6442,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,6442,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,6443,0)
 ;;=C92.41^^26^402^19
 ;;^UTILITY(U,$J,358.3,6443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6443,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,6443,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,6443,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,6444,0)
 ;;=C92.40^^26^402^20
 ;;^UTILITY(U,$J,358.3,6444,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6444,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,6444,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,6444,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,6445,0)
 ;;=D56.0^^26^402^21
 ;;^UTILITY(U,$J,358.3,6445,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6445,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,6445,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,6445,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,6446,0)
 ;;=D63.1^^26^402^23
 ;;^UTILITY(U,$J,358.3,6446,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6446,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,6446,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,6446,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,6447,0)
 ;;=D63.0^^26^402^24
 ;;^UTILITY(U,$J,358.3,6447,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6447,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,6447,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,6447,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,6448,0)
 ;;=D63.8^^26^402^22
 ;;^UTILITY(U,$J,358.3,6448,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6448,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,6448,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,6448,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,6449,0)
 ;;=C22.3^^26^402^25
 ;;^UTILITY(U,$J,358.3,6449,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6449,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,6449,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,6449,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,6450,0)
 ;;=D61.9^^26^402^26
 ;;^UTILITY(U,$J,358.3,6450,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6450,1,3,0)
 ;;=3^Aplastic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,6450,1,4,0)
 ;;=4^D61.9
 ;;^UTILITY(U,$J,358.3,6450,2)
 ;;=^5002342
 ;;^UTILITY(U,$J,358.3,6451,0)
 ;;=D56.1^^26^402^28
 ;;^UTILITY(U,$J,358.3,6451,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6451,1,3,0)
 ;;=3^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,6451,1,4,0)
 ;;=4^D56.1
 ;;^UTILITY(U,$J,358.3,6451,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,6452,0)
 ;;=C83.79^^26^402^29
 ;;^UTILITY(U,$J,358.3,6452,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6452,1,3,0)
 ;;=3^Burkitt Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,6452,1,4,0)
 ;;=4^C83.79
 ;;^UTILITY(U,$J,358.3,6452,2)
 ;;=^5001600
 ;;^UTILITY(U,$J,358.3,6453,0)
 ;;=C83.70^^26^402^30
 ;;^UTILITY(U,$J,358.3,6453,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6453,1,3,0)
 ;;=3^Burkitt Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,6453,1,4,0)
 ;;=4^C83.70
 ;;^UTILITY(U,$J,358.3,6453,2)
 ;;=^5001591
 ;;^UTILITY(U,$J,358.3,6454,0)
 ;;=D09.0^^26^402^37
 ;;^UTILITY(U,$J,358.3,6454,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6454,1,3,0)
 ;;=3^Carcinoma in Situ of Bladder
 ;;^UTILITY(U,$J,358.3,6454,1,4,0)
 ;;=4^D09.0
 ;;^UTILITY(U,$J,358.3,6454,2)
 ;;=^267742
 ;;^UTILITY(U,$J,358.3,6455,0)
 ;;=D06.9^^26^402^38
 ;;^UTILITY(U,$J,358.3,6455,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6455,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix
 ;;^UTILITY(U,$J,358.3,6455,1,4,0)
 ;;=4^D06.9
 ;;^UTILITY(U,$J,358.3,6455,2)
 ;;=^5001941
 ;;^UTILITY(U,$J,358.3,6456,0)
 ;;=D06.0^^26^402^40
 ;;^UTILITY(U,$J,358.3,6456,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6456,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,6456,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,6456,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,6457,0)
 ;;=D06.1^^26^402^41
 ;;^UTILITY(U,$J,358.3,6457,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6457,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,6457,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,6457,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,6458,0)
 ;;=D06.7^^26^402^39
 ;;^UTILITY(U,$J,358.3,6458,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6458,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,6458,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,6458,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,6459,0)
 ;;=D04.9^^26^402^42
 ;;^UTILITY(U,$J,358.3,6459,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6459,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,6459,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,6459,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,6460,0)
 ;;=C91.11^^26^402^45
 ;;^UTILITY(U,$J,358.3,6460,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6460,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,6460,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,6460,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,6461,0)
 ;;=C91.10^^26^402^46
 ;;^UTILITY(U,$J,358.3,6461,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,6461,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,6461,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,6461,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,6462,0)
 ;;=C92.11^^26^402^47
